人 CCL8 抗体对
01AB00173
CCL8, also known as monocyte chemoattractant protein-2 (MCP-2), is a chemokine that plays a crucial role in immune responses and is involved in various diseases, particularly cancer. It functions primarily by attracting immune cells, such as monocytes and macrophages, to sites of inflammation or tumor growth. Elevated levels of CCL8 have been associated with tumor progression and metastasis, particularly in cancers like glioblastoma and diffuse large B-cell lymphoma (DLBCL). In glioblastoma, CCL8 secreted by tumor-associated macrophages enhances tumor invasion and stemness through ERK1/2 signaling pathways. In DLBCL, higher CCL8 expression correlates with poor prognosis and is linked to M2 macrophage recruitment, which promotes a tumor-supportive microenvironment. Thus, CCL8 serves as both a biomarker for disease progression and a potential therapeutic target in cancer treatment.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- CCL8
- 基因别名
- MCP2; SCYA10; SCYA8
- 蛋白别名
- C-C motif chemokine ligand 8; CCL8
- UniProt
- P80075
- 物种
- Human
产品详情
- 靶点名称
- CCL8
- 蛋白名称
- C-C motif chemokine ligand 8
- 蛋白别名
- C-C motif chemokine 8; HC14; Monocyte chemoattractant protein 2; Monocyte chemotactic protein 2; MCP-2; Small-inducible cytokine A8) [Cleaved into: MCP-2(6-76]
- 靶点基因名
- CCL8
- 基因别名
- MCP2; SCYA10; SCYA8
- UniProt
- P80075
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
CCL8, also known as monocyte chemoattractant protein-2 (MCP-2), is a chemokine that plays a crucial role in immune responses and is involved in various diseases, particularly cancer. It functions primarily by attracting immune cells, such as monocytes and macrophages, to sites of inflammation or tumor growth. Elevated levels of CCL8 have been associated with tumor progression and metastasis, particularly in cancers like glioblastoma and diffuse large B-cell lymphoma (DLBCL). In glioblastoma, CCL8 secreted by tumor-associated macrophages enhances tumor invasion and stemness through ERK1/2 signaling pathways. In DLBCL, higher CCL8 expression correlates with poor prognosis and is linked to M2 macrophage recruitment, which promotes a tumor-supportive microenvironment. Thus, CCL8 serves as both a biomarker for disease progression and a potential therapeutic target in cancer treatment.